Table 1.
Baseline characteristics of adults in the prospective population-based cohort study, stratified by use of antithrombotic therapy
| Used antithrombotic therapy after presentation (n=61) | Never used antithrombotic therapy after presentation (n=239) | p value | ||
|---|---|---|---|---|
| Sex | 0·13 | |||
| Women | 27 (44%) | 132 (55%) | .. | |
| Men | 34 (56%) | 107 (45%) | .. | |
| Age, years | 57·0 (45·5–65·0) | 39·0 (31·0–53·0) | <0·0001 | |
| Comorbidities | ||||
| Hypertension | 32 (52%) | 28 (12%) | <0·0001 | |
| Ischaemic heart disease | 24 (39%) | 6 (3%) | <0·0001 | |
| Ischaemic stroke or transient ischaemic attack | 21 (34%) | 4 (2%) | <0·0001 | |
| Atrial fibrillation | 7 (11%) | 1 (<1%) | <0·0001 | |
| Mechanical heart valve | 0 | 0 | .. | |
| Type of CCM presentation | ||||
| Incidental | 39 (64%) | 90 (38%) | <0·0001 | |
| Focal neurological deficit | 4 (7%) | 27 (11%) | 0·28 | |
| Epileptic seizure | 13 (21%) | 75 (31%) | 0·12 | |
| Intracranial haemorrhage | 5 (8%) | 47 (20%) | 0·035 | |
| CCM imaging characteristics | ||||
| Multiple CCM | 16 (26%) | 81 (34%) | 0·25 | |
| Brainstem CCM | 8 (13%) | 26 (11%) | 0·62 | |
Data are n (%) or median (IQR). CCMs=cerebral cavernous malformations.